



121 State Street
Albany, New York 12207-1693
Tel: 518-436-0751
Fax: 518-436-4751

June 5, 2023

RE: AN ACT to amend the insurance law and the social services law, in relation to requiring certain insurance policies and Medicaid to allow patients a one hundred twenty-day window for additional breast exams when the provider deems another breast exam is needed

A.1696 (Hunter)
S.2465 (Persaud)

MEMORANDUM IN OPPOSITION

Submitted on behalf of the Blue Cross and Blue Shield Plans

The New York State Conference of Blue Cross and Blue Shield Plans opposes enactment of this bill because it is unnecessary in light of existing state and federal requirements. Specifically, this bill would amend current law that requires coverage of mammograms (which may be provided by breast tomosynthesis) based on patients' risk factors and ages, to extend coverage mandates to also include additional screenings for breast cancer: (1) based on current age and risk standards, as well as the presence of dense breast tissue; and (2) within 120 days of a mammogram that showed abnormalities due to dense breast tissue or when "the provider deems another mammogram is needed."

While the goal of the bill – promoting early detection of breast cancer – is laudable, the Patient Protection and Affordable Care Act ("ACA") already requires coverage of tests recommended by independent medical experts who regularly review guidelines. Notably, as the bill does not restrict its coverage mandate to "essential health benefits" under the ACA, it would result in significant

costs to the State. Additionally, New York State presently requires coverage in accordance with federally accepted clinical guidelines, and prohibits the imposition of deductibles and copayments for any covered screening and diagnostic imaging for the detection of breast cancer.

Since 2010, the ACA has required health plans to cover all screening tests for breast cancer that are designated as “A and B Recommendations” by the United States Preventive Services Task Force (“USPSTF”). The USPSTF is an independent panel of national experts in prevention and evidence-based medicine that promulgates standards in accordance with processes that “align with the National Academy of Medicine’s (formerly the Institute of Medicine) recommendations for guideline development.”¹ Pursuant to the ACA, insurers must cover such services with A or B Recommendations, which are considered “essential health benefits” and are not subject to copays or deductibles.²

Current USPSTF recommendations find that “evidence is insufficient to assess the balance of benefits and harms of adjunctive screening for breast cancer using breast ultrasonography, magnetic resonance imaging, DBT [dense breast tomosynthesis], or other methods in women identified to have dense breasts on an otherwise negative screening mammogram.”³ Such recommendations are in line with those of the American College of Obstetricians and Gynecologists, which state that “[w]omen with dense breasts have a modestly increased risk of breast cancer and experience reduced sensitivity of mammography to detect breast cancer. However, evidence is lacking to advocate for additional testing until there are clinically validated data that indicate improved screening outcomes.... The American College of Obstetricians and Gynecologists does not recommend routine use of alternative or adjunctive tests to screening mammography in women with dense breasts who are asymptomatic and have no additional risk factors.”⁴

Notably, USPSTF recommendations regarding breast cancer screenings are presently being updated.⁵ This process is indicative of the importance of utilizing USPSTF recommendations for determining coverage of all preventive screenings and tests – namely, to premise such coverage on empirical, clinically based, and peer-reviewed independent guidelines that are revised as our

1 U.S. Preventative Services Task Force, *Standards for Guideline Development*, available at <https://www.uspreventiveservicestaskforce.org/uspstf/about-uspstf/methods-and-processes/standards-guideline-development>.

2 American Cancer Society, *Insurance Coverage for Colorectal Cancer Screening*, available at [https://www.cancer.org/cancer/colon-rectal-cancer/detection-diagnosis-staging/screening-coverage-laws.html#:~:text=The%20Affordable%20Care%20Act%20\(ACA,Services%20Task%20Force%20\(USPSTF\)](https://www.cancer.org/cancer/colon-rectal-cancer/detection-diagnosis-staging/screening-coverage-laws.html#:~:text=The%20Affordable%20Care%20Act%20(ACA,Services%20Task%20Force%20(USPSTF)).

3 U.S. Preventative Services Task Force, “Final Recommendation Statement - Breast Cancer: Screening,” Jan. 1, 2016, available at <https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/breast-cancer-screening>.

4 The American College of Obstetricians and Gynecologists, “Management of Women With Dense Breasts Diagnosed by Mammography: Committee Opinion Number 265,” Reaffirmed in 2020, available at <https://www.acog.org/clinical/clinical-guidance/committee-opinion/articles/2015/03/management-of-women-with-dense-breasts-diagnosed-by-mammography>.

5 *Id.*

scientific understanding of medical conditions evolves. However, as this bill does not restrict coverage mandates to screenings as recommended by the USPSTF, this bill could result in significant costs to the State. The Affordable Care Act provides that, while states may require coverage of benefits in addition to essential health benefits, a “State shall make payments (I) to an individual enrolled in a qualified health plan offered in such State; or (II) on behalf of an individual described in subclause (I) directly to the qualified health plan in which such individual is enrolled; to defray the cost of any additional benefits.”⁶ Therefore, pursuant to this section, the State would be responsible for the cost of any such screenings to individual and small group commercial insurance products.

Further, since 2017, New York has required the provision of breast cancer screenings as recommended by the USPSTF and the federal Health Resources and Services Administration (“HRSA”).⁷ When covered, such screening and diagnostic imaging for the detection of breast cancer – including diagnostic mammograms, breast ultrasounds, or magnetic resonance imaging – cannot be subject to copayments or deductibles.⁸ Finally, it is important to note that USPSTF and HRSA guidelines establish minimum coverage requirements, and additional screenings following a mammographic determination of dense breast tissue are frequently determined to be medically necessary; and are therefore often covered services that are not subject to coinsurance.

For the foregoing reasons, the Blue Cross and Blue Shield Plans urge that this bill not be enacted.

Respectfully submitted,

HINMAN STRAUB ADVISORS, LLC
Legislative Counsel for the Blue Cross and Blue Shield Plans

4862-2681-2958, v. 2

⁶ 42 USC §18031(d)(3)(b).

⁷ NY Insurance Law §§3216, 3221 and 4303.

⁸ *Id.*